Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Yu Mironov

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Kardiologiia|January 10, 2019
N Yu Mironov, S P Golitsyn
Kardiologiia|March 15, 2017
[Overwiew of New Clinical Guidelines for the Diagnosis and Treatment of Supraventricular Tachycardias (2015) of the American College of Cardiology/American Heart Association/Society for Heart Rhythm Disturbances (ACC/AHA/HRS)]N Yu Mironov, S P Golitsyn
Kardiologiia|October 28, 2015
[Congenital Cardiac Conduction Abnormalities]N Yu Mironov, E S Berezina, S P Golitsyn
Bulletin of Experimental Biology and Medicine|April 11, 2023
The Dependence of the Electrophysiological Effects of Class III Antiarrhythmic Drug Refralon on the Frequency of Myocardium ActivationD V Abramochkin, O B Pustovit, N Yu Mironov, et al.
Kardiologiia|May 8, 2020
[Cardiac magnetic resonance imaging with contrast enhancement in treatment of atrial fibrillation]O P Aparina, N Yu Mironov, E A Fedorova, et al.
Terapevticheskii Arkhiv|April 1, 2015
[Refralon (niferidil) is a new class III antiarrhythmic agent for pharmacological cardioversion for persistent atrial fibrillation and atrial flutter]E B Maykov, Yu A Yuricheva, N Yu Mironov, et al.
Kardiologiia|July 20, 2023
Early initiation of anti-relapse antiarrhythmic therapy in patients with atrial fibrillation and flutter after pharmacological cardioversion with refralonD A Gagloeva, Kh M Dzaurova, M A Zelberg, et al.
Kardiologiia|August 10, 2019
[Electrophysiological Cardiac Parameters and Results of Antiarrhythmic Treatment in Patients with Paroxysmal Atrial Fibrillation (Lone and Associated with Arterial Hypertension)]E S Mironova, N Yu Mironov, N A Mironova, et al.
Kardiologiia|January 15, 2016
[Ventricular Tachycardia as a First Manifestation of Myotonic Dystrophy]N Yu Mironov, N A Mironova, S F Sokolov, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Kardiologiia|January 10, 2019
N Yu Mironov, S P Golitsyn
Kardiologiia|March 15, 2017
[Overwiew of New Clinical Guidelines for the Diagnosis and Treatment of Supraventricular Tachycardias (2015) of the American College of Cardiology/American Heart Association/Society for Heart Rhythm Disturbances (ACC/AHA/HRS)]N Yu Mironov, S P Golitsyn
Kardiologiia|October 28, 2015
[Congenital Cardiac Conduction Abnormalities]N Yu Mironov, E S Berezina, S P Golitsyn
Bulletin of Experimental Biology and Medicine|April 11, 2023
The Dependence of the Electrophysiological Effects of Class III Antiarrhythmic Drug Refralon on the Frequency of Myocardium ActivationD V Abramochkin, O B Pustovit, N Yu Mironov, et al.
Kardiologiia|May 8, 2020
[Cardiac magnetic resonance imaging with contrast enhancement in treatment of atrial fibrillation]O P Aparina, N Yu Mironov, E A Fedorova, et al.
Terapevticheskii Arkhiv|April 1, 2015
[Refralon (niferidil) is a new class III antiarrhythmic agent for pharmacological cardioversion for persistent atrial fibrillation and atrial flutter]E B Maykov, Yu A Yuricheva, N Yu Mironov, et al.
Kardiologiia|July 20, 2023
Early initiation of anti-relapse antiarrhythmic therapy in patients with atrial fibrillation and flutter after pharmacological cardioversion with refralonD A Gagloeva, Kh M Dzaurova, M A Zelberg, et al.
Kardiologiia|August 10, 2019
[Electrophysiological Cardiac Parameters and Results of Antiarrhythmic Treatment in Patients with Paroxysmal Atrial Fibrillation (Lone and Associated with Arterial Hypertension)]E S Mironova, N Yu Mironov, N A Mironova, et al.
Kardiologiia|January 15, 2016
[Ventricular Tachycardia as a First Manifestation of Myotonic Dystrophy]N Yu Mironov, N A Mironova, S F Sokolov, et al.
Pageof 1